SAR studies of 1,5-diarylpyrazole-based CCK1 receptor antagonists

Bioorganic and Medicinal Chemistry Letters

Volumn 17, Issue 23, 2007, Pages 6493-6498

  Gomez, Laurent ^a   Hack, Michael D ^a   McClure, Kelly ^a   Sehon, Clark ^a   Huang, Liming ^a   Morton, Magda ^a   Li, Lina ^a   Barrett, Terrance D ^a   Shankley, Nigel ^a   Breitenbucher, J Guy ^a  

^a JOHNSON AND JOHNSON PHARMACEUTICAL RESEARCH AND DEVELOPMENT   (United States)

Author keywords

Alkene analogs; CCK1; Cholecystokinin; Pyrazole

Indexed keywords

1,5 DIARYLPYRAZOLE DERIVATIVE; CHOLECYSTOKININ A RECEPTOR ANTAGONIST; DEVAZEPIDE; LINTITRIPT; UNCLASSIFIED DRUG;

ALKYLATION; ARTICLE; DESS MARTIN OXIDATION; DRUG HYDROLYSIS; DRUG POTENCY; DRUG STRUCTURE; DRUG SYNTHESIS; ENANTIOMER; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; STRUCTURE ACTIVITY RELATION; SUBSTITUTION REACTION;

ANIMALS; HUMANS; PYRAZOLES; RATS; RECEPTOR, CHOLECYSTOKININ A; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 35648987946     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2007.09.093     Document Type: Article

References (18)

1. Ivy A.C., and Olderg E. Am. J. Physiol. 86 (1928) 599
2. Jorpes E., and Mutt V. Acta Physiol. Scand. 66 (1966) 196
3. Harper A.A., and Raper H.S. J. Physiol. 102 (1943) 115
4. Varga G. Curr. Opin. Investig. Drugs 3 (2002) 621
5. Herranz R. Med. Res. Rev. 23 (2003) 559
6. Varga G., Balint A., Burghardt B., and D'Amato M. Br. J. Pharmacol. 141 (2004) 1275
7. Peter S.A.S., D'Amato M., and Beglinger C. Dig. Dis. 24 (2006) 70
8. McClure K., Hack M., Huang L., Sehon C., Morton M., Li L., Barrett T.D., Shankley N., and Breitenbucher J.G. Bioorg. Med. Chem. Lett. 16 (2006) 72
9. Sehon C., McClure K., Hack M., Morton M., Gomez L., Li L., Barrett T.D., Shankley N., and Breitenbucher J.G. Bioorg. Med. Chem. Lett. 16 (2006) 77
10. Murray W.V., Hadden S.K., and Wachter M.P. J. Heterocycl. Chem. 27 (1990) 1933
11. Evans D.A., Ennis M.D., and Mathre D.J. J. Am. Chem. Soc. 104 (1981) 1737
12. Ager D.J., Prakash I., and Schaad D.R. Chem. Rev. 96 (1996) 835
13. Data generated using our assay conditions. For details, see:. Morton M.F., Pyati J., Dai H., Li L., Moreno V., and Shankley N.P. Br. J. Pharmacol. 145 (2005) 374
14. MOE (The Molecular Operating Environment) Version 2006.08, software available from Chemical Computing Group Inc., 1010 Sherbrooke Street West, Suite 910, Montreal, Canada H3A 2R7. 〈http://www.chemcomp.com〉.
15. It should be noted that 3,4-diCl substitutions on the B-ring display comparable activities than 4-Cl and 4-Me (see supplementary material).
16. Lazardis T. Curr. Org. Chem. 6 (2002) 1319
17. 1 receptor antagonists, see: Morton, M. F.; Barrett, T.; Yan, W.; Freedman, J. M.; Lagaud, G.; Prendergast, C. E.; Moreno, V.; Pyati, J.; Figueroa, K.; Li, L.; Wu, X.; Rizzolio, M.; Breitenbucher, J. G.; McClure, K.; Shankley, N. P. J. Pharmacol. Exp. Ther. 2007, in press, doi:10.1124/jpet.107.124578.
18. 2 binding data are contained in supplementary material.